AbbVie Inc. is 58.4x more valuable than Protagonist Therapeutics, Inc by market capitalization ($397.44 B vs $6.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PTGX | ABBV |
|---|---|---|
| Market cap | $6.80 B | $397.44 B |
| US-listed rank | #1171 | #28 |
| Revenue (latest FY) | $46.02M | $61.16B |
| Net income (latest FY) | -$130.15M | $4.23B |
| Net margin | -282.8% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 668 | 1,008 |
AbbVie Inc. is 58.4x more valuable than Protagonist Therapeutics, Inc by market capitalization ($397.44 B vs $6.80 B).
In their latest fiscal years, Protagonist Therapeutics, Inc reported $46.02M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Protagonist Therapeutics, Inc and AbbVie Inc., or browse the full rankings.